Watch EBS. Know when insiders buy.
One email the day a filing lands. Free.
EBS
Emergent BioSolutions Inc.
6.23
+0.36 +6.13%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
15
FLAG · shorts 15
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $319.4MP/E —DIV YIELD —FCF YIELD 26.89%REV TTM $770.2M −9.6%NET INCOME −$176.8M −226.7%NET DEBT $450M52W 4.45 – 13.90SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $234.3M | +66.3% | 58.6% | −$125.1M | −$180.2M | — | -3.49 | $56.1M | $2.1M | $54M | Aug 6 |
| Q1 2026 · Mar 31 | $156.1M | −29.7% | 53.9% | $10.5M | $6.8M | −90.0% | 0.07 | −$33.8M | $2.4M | −$36.2M | Aug 6 |
| Q4 2025 · Dec 31derived | $148.7M | −23.6% | 42.9% | −$27.9M | −$54.6M | — | -0.96 | $77.7M | $3.9M | $73.8M | Feb 27 |
| Q3 2025 · Sep 30 | $231.1M | −21.3% | 62.8% | $76.5M | $51.2M | −55.4% | 0.91 | −$2.3M | $3.4M | −$5.7M | Oct 30 |
| Q2 2025 · Jun 30 | $140.9M | −44.7% | 52.5% | $1.6M | −$12M | — | -0.22 | $106.4M | $2.9M | $103.5M | Aug 6 |
| Q1 2025 · Mar 31 | $222.2M | −26.0% | 60.2% | $49.9M | $68M | +655.6% | 1.19 | −$11.2M | $3.6M | −$14.8M | Aug 6 |
| Q4 2024 · Dec 31derived | $194.7M | −29.6% | 39.4% | −$9.5M | −$31.3M | — | -0.57 | −$79.9M | $1.7M | −$81.6M | Feb 27 |
| Q3 2024 · Sep 30 | $293.8M | +8.6% | 54.9% | $64.5M | $114.8M | — | 2.06 | $153.7M | $5.8M | $147.9M | Oct 30 |
| Q2 2024 · Jun 30 | $254.7M | — | -18.8% | −$203.5M | −$283.1M | — | -5.38 | $47.5M | $4.6M | $42.9M | Oct 30 |
| Q1 2024 · Mar 31 | $300.4M | — | 49.2% | $39.8M | $9M | — | 0.17 | −$62.6M | $10.8M | −$73.4M | Oct 30 |
| Q4 2023 · Dec 31derived | $276.6M | — | 30.7% | −$43.8M | −$49.5M | — | -0.88 | $32.1M | $11.4M | $20.7M | Feb 27 |
| Q3 2023 · Sep 30 | $270.5M | — | 32.2% | −$242.1M | −$263.4M | — | -5.08 | $60M | $12.6M | $47.4M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $742.9M | 56.1% | $100.1M | $52.6M | 7.1% | 0.93 | $170.6M | $13.8M | $156.8M | $24.9M | — |
| FY2024 · to Dec 31 | $1B | 34.7% | −$108.7M | −$190.6M | -18.3% | -3.60 | $58.7M | $22.9M | $35.8M | $0 | — |
| FY2023 · to Dec 31 | $1B | 30.3% | −$726.4M | −$760.5M | -72.5% | -14.85 | −$206.3M | $51.6M | −$257.9M | $0 | — |
| FY2022 · to Dec 31 | $1.1B | 34.3% | −$170M | −$211.6M | -18.9% | -4.22 | −$34.1M | $115.8M | −$149.9M | $82.1M | — |
| FY2021 · to Dec 31 | $1.8B | 50.3% | $341.4M | $219.5M | 12.4% | 4.06 | $320.2M | $224.1M | $96.1M | $106M | — |
| FY2020 · to Dec 31 | $1.6B | 58.7% | $438.5M | $305.8M | 19.4% | 5.68 | $536.9M | $141.9M | $395M | $0 | — |
Every number comes from Emergent BioSolutions Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.